Levente Pál K.
- Country
- Hungary
- Department
- NA
Research Overview
- Efficacy and Safety Evaluation of JNJ-77242113 Versus Placebo and Deucravacitinib in Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Controlled Trial
- Efficacy and Safety Evaluation of JNJ-77242113 in Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
- Efficacy and Safety of Ruxolitinib Cream in Adults with Moderate Atopic Dermatitis: A Phase 3b Double-Blind, Randomized, Vehicle-Controlled Study
Data & Insights
Has run more than one trial at 145 of 371 partner sites.
Specializations
Psoriasis Research
This investigator specializes in conducting advanced research on moderate to severe plaque psoriasis, with particular emphasis on evaluating novel therapeutic approaches for patients with varying disease presentations.
- Standard and specialized psoriasis treatments
- Special area psoriasis management
- Weight-adjusted treatment protocols
The research encompasses both conventional plaque psoriasis cases and specialized conditions affecting specific body areas.
Dermatological Conditions
The investigator focuses on comprehensive research in atopic dermatitis, exploring innovative therapeutic solutions for patients with moderate to severe manifestations of the condition.
- Novel topical treatments
- Long-term disease management
- Treatment-resistant cases
Research extends to patients who have shown inadequate response to conventional therapies.
Therapeutic Innovation
The investigator evaluates emerging therapeutic agents through various clinical investigations, focusing on both established and experimental treatment approaches.
- Novel biological therapies
- Investigational compounds
- Long-term efficacy studies
Research includes assessment of treatment durability and therapeutic response patterns.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.